{"entity":{"id":"al-605","kind":"drug","name":"AL-605","aka":[],"tldr":"AL-605 is an experimental small molecule from Alaw Therapeutics, in phase 1 trials for HR-positive breast cancer after CDK4/6 inhibitors with CCNE1 amplification or overexpression, CCNE1-amplified ovarian cancer and endometrial cancer and other cancers.","summary":"AL-605 is a small molecule from Alaw Therapeutics. A selective, brain-penetrant CDK2 inhibitor designed to target CDK2-dependent tumour growth, including cyclin E-driven cancers and settings where CDK2 activation drives resistance. Its furthest stage is phase 1, for HR-positive breast cancer after CDK4/6 inhibitors with CCNE1 amplification or overexpression, CCNE1-amplified ovarian cancer, endometrial cancer and gastric cancer. No clinical trial naming it is registered on ClinicalTrials.gov. Company release of 29 May 2026: first patients dosed in a phase 1a/b trial in CCNE1-amplified solid tumours; interim data expected in the second half of 2026. It has not been shown to work in people.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Alaw Therapeutics: alawtx.com","url":"https://www.alawtx.com/pipeline"},{"label":"Alaw Therapeutics: alawtx.com","url":"https://www.alawtx.com/news1/alaw-therapeutics-announces-two-major-pipeline-milestones-advancing-brain-penetrant-cdk-oncology-programs"}],"tags":["pipeline"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["cdk2"],"drugs":[],"companies":["alaw-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"AL-605","modality":"Small molecule","mechanism":"A selective, brain-penetrant CDK2 inhibitor designed to target CDK2-dependent tumour growth, including cyclin E-driven cancers and settings where CDK2 activation drives resistance.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/al-605/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"cdk2","kind":"target","name":"CDK2","route":"/targets/cdk2/"}],"company":[{"id":"alaw-therapeutics","kind":"company","name":"Alaw Therapeutics","route":"/companies/alaw-therapeutics/"}]}}